<DOC>
	<DOCNO>NCT00537290</DOCNO>
	<brief_summary>RITuximab AntiphosPholipid Syndrome ( RITAPS ) Study design evaluate whether medication call rituximab would reduce sign symptom antiphospholipid antibody ( aPL ) -related certain clinical problem .</brief_summary>
	<brief_title>A Pilot Study Rituximab Anticoagulation Resistant Manifestations Antiphospholipid Syndrome</brief_title>
	<detailed_description>Persistently antiphospholipid antibody ( aPL ) -positive patient , age 18 - 75 year age , anticoagulation-resistant manifestation APS fulfil protocol define study inclusion criterion receive two dos Rituximab , follow 6 12 month clinical safety outcome , respectively . Patients eligible take part study blood test persistently positive aPL one aPL-related clinical problem ( ) list : low platelet ( blood cell involve prevention bleed ) count ; anemia ( deficiency red blood cell ) ; heart valve disease ; skin ulcer ; kidney smal vessel blood clot ; and/or memory problem .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Positive aPL profile define : Positive lupus anticoagulant test define International Society Thrombosis Haemostasis , two occasion , least 12 week apart and/or Positive anticardiolipin antibody ( aCL ) immunoglobulin G ( Ig ) G/M/A isotype , present &gt; 40U , two occasion , least 12 week apart and/or Positive antiβ2glycoproteinI ( aβ2GPI ) IgG/M/A isotype , present &gt; 40U , two occasion , least 12 week apart AND Clinical feature attributable aPL resistant warfarin and/or heparin : Persistent thrombocytopenia and/or Persistent autoimmune hemolytic anemia and/or Cardiac valve disease and/or Chronic skin ulcer and/or Renal thrombotic microangiopathy and/or Cognitive dysfunction with/without white matter change Exclusion Criteria ( select ) : &gt; 4/11 American College Rheumatology Classification Criteria SLE Acute thrombosis History stroke ( patient cognitive dysfunction ) Positive Hepatitis B C serology History positive HIV Acute chronic pancreatitis Treatment investigational agent within 4 week screen Receipt live vaccine within 4 week prior randomization Previous Treatment Rituximab ( MabThera® / Rituxan® ) Previous treatment Natalizumab ( Tysabri® ) Known active bacterial , viral fungal mycobacterial , infection Pregnancy Concomitant malignancies previous malignancy , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix History psychiatric disorder would interfere normal participation protocol Significant cardiac pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>antiphospholipid syndrome</keyword>
</DOC>